H-VISNDVCAQV-OH
Ref. 3D-PP46024
| 1mg | 232.00 € | ||
| 10mg | 273.00 € | ||
| 100mg | 497.00 € |
Product Information
- NH2-Val-Ile-Ser-Asn-Asp-Val-Cys-Ala-Gln-Val-OH
Peptide H-VISNDVCAQV-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-VISNDVCAQV-OH include the following: A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A* 0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer RL Prue, F Vari , KJ Radford , H Tong - Journal of , 2015 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/FullText/2015/02000/A_Phase_I_Clinical_Trial_of_CD1c__BDCA_1__.4.aspx A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. PM Arlen, JL Gulley , C Parker, L Skarupa - Clinical cancer research , 2006 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/12/4/1260/283410 Real time detection of peptide-MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no, effect on stability KM Miles, JJ Miles , F Madura, AK Sewell , DK Cole - Molecular immunology, 2011 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0161589010006073 A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols K Lundberg, AK Roos, M Pavlenko , C Leder - Vaccine, 2009 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X09000164 Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer JL Gulley , PM Arlen, A Bastian, S Morin, J Marte - Clinical Cancer , 2005 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/11/9/3353/188846 Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand J Dannull, S Nair, Z Su, D Boczkowski, C DeBeck - Blood, 2005 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/105/8/3206/20581 Peptides for vaccine development IW Hamley - ACS Applied Bio Materials, 2022 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acsabm.1c01238 HLA typing demands for peptide-based anti-cancer vaccine D Nagorsen, E Thiel - Cancer Immunology, Immunotherapy, 2008 - Springerhttps://link.springer.com/article/10.1007/s00262-008-0493-6 Dendritic cell-based immunotherapy of hormone refractory prostate carcinoma (HRPCa)-a pilot trial B Hildenbrand, A Langenkamp, B Sauer, C Stoll - Cancer Cell , 2004 - Springerhttps://link.springer.com/article/10.1186/1475-2867-4-S1-S39 Peptide-based therapeutics in cancer therapy AT Jalil, MA Abdulhadi , LR Al-Ameer , WM Taher - Molecular , 2023 - Springerhttps://link.springer.com/article/10.1007/s12033-023-00873-1 The bright side of chemistry: Exploring synthetic peptide-based anticancer vaccines A D'Aniello, A Del Bene, S Mottola - Journal of Peptide , 2024 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/psc.3596
Chemical properties
Technical inquiry about: 3D-PP46024 H-VISNDVCAQV-OH
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
